Vir Biotechnology, Inc. (VIR) Form 8-K — Oct 28, 2026
Vir Biotechnology's board approved an expansion from eight to nine members and appointed Suzanne Topalian, M.D., as a Class III director effective October 27, 2026, serving until the 2028 annual meeting. Dr. Topalian also joins the Board's Science and Technology Committee and will receive standard non-employee director cash and equity compensation, including automatic stock option and RSU awards under the 2019 Equity Incentive Plan.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.